Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PBD 2131

Drug Profile

PBD 2131

Alternative Names: HemoMexI; HemoMexS; PAM-200; Pandimex; PBD-1226; PBD2131

Latest Information Update: 11 Mar 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Panagin Pharmaceuticals
  • Class Antineoplastics; Phytotherapies
  • Mechanism of Action Apoptosis stimulants; Caspase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer; Neutropenia; Solid tumours

Most Recent Events

  • 11 Mar 2015 No recent reports on development identified - Registered for Cancer and Neutropenia in Georgia (PO)
  • 11 Mar 2015 No recent reports on development identified - Registered for Solid tumours and Neutropenia in Georgia and Uzbekistan (IV)
  • 20 Feb 2004 Preclinical trials in Cancer in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top